Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions

Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions

Abstract Background The introduction of antibody–drug conjugates represents a significant advancement in targeted therapy of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Our study aims to investigate the role of the DNA damage response pathway and the impact of PARP1 inhibiti...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Ghelli Luserna di Rorà, Mouna Jandoubi, Antonella Padella, Anna Ferrari, Andrea Marranci, Cristina Mazzotti, Francesco Olimpico, Martina Ghetti, Lorenzo Ledda, Maria Teresa Bochicchio, Matteo Paganelli, Michele Zanoni, Alessandro Cafaro, Chiara Servili, Sara Galimberti, Michele Gottardi, Michela Rondoni, Mauro Endri, Daniela Onofrillo, Ernesta Audisio, Giovanni Marconi, Giorgia Simonetti, Giovanni Martinelli
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Translational Medicine
Subjects:
Antibody–drug conjugates
PARP1 inhibition
DNA damage response pathway
Acute myeloid leukemia (AML)
Acute lymphoblastic leukemia (ALL)
Online Access:https://doi.org/10.1186/s12967-024-05838-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-024-05838-9

Similar Items